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The aim of the present work was to compare hepatitis C prevalence, genotypes, and risk factors between 
prisoners and non-prisoners in the city of Colatina, Espírito Santo, Brazil. This cross-sectional study 
involved approximately 1,600 residents and 730 prisoners, all of whom were living in Colatina. The 
percentage of individuals who tested positive for anti-HCV was 0.1% (2/1,600) in the non-prisoner group 
and 1.0% (7/730) in the prisoner group, confirming a higher risk of hepatitis C in the latter group. The 
percentage of subjects who progressed to HCV-RNA negative was 11.1% (1/9), confirming the high 
probability of evolution to chronicity. Genotype 1 was the most predominant genotype found. Factors 
associated with increased risk of hepatitis C were being male, being institutionalized, having an income 
of less than three minimum wages, having low educational attainment, and using injected drugs. Alcohol 
use, pain in the liver, migraine, and reported history of hepatitis were markedly associated with hepatitis 
C. The prison population tested positive for anti-HCV at a higher rate than the non-prison population.
Uniterms: Hepatitis C/prevalence. Hepatitis C/genotypes. Hepatitis C/risk factors. Hepatitis C/symptoms. 
Anti-HCV. Prison population/risks evaluation.
O objetivo do presente trabalho foi comparar a prevalência, os genótipos e fatores de risco da hepatite C 
entre a população em geral e os presos na cidade de Colatina, Espírito Santo, Brasil. O presente estudo 
é transversal e comparou cerca de 1.600 moradores e 730 prisioneiros, todos eles vivendo em Colatina. 
A prevalência de anticorpos anti-HCV positivo foi de 0,1% (2/1.600), na população em geral, e de 
1,0% (7/730) entre os presos, o que confirma o elevado risco nesse grupo. A percentagem de indivíduos 
que apresentam RNA-HCV negativo foi de 11,1% (1/9), confirmando a alta taxa de evolução para a 
cronicidade. O genótipo predominante foi o I. Fatores associados ao aumento do risco de hepatite C foram 
do sexo masculino, sendo institucionalizado, com renda de até três salários mínimos, baixa escolaridade 
e uso de drogas injetáveis. O uso de álcool, dor no fígado, enxaqueca e relato de histórias de hepatite 
apresentaram associação significativa com a hepatite C. A população carcerária teve maiores taxas de 
positividade para o anti-HCV do que a população não-prisional pesquisada.
Unitermos: Hepatite C./prevalência. Hepatite C./genótipos. Hepatite C./fatores de risco. Hepatitis C/
sintomas. Anti-HCV. População carcerária/avaliação de riscos.
INTRODUCTION
Viral hepatitis C, isolated from viral RNA, is a 
relatively recent discovery (Choo et al., 1989). It has been 
cited often as a major determinant of chronic liver disease 
(Martins, Schiavon, Schiavon, 2011) and as a worldwide 
public health concern (Sy, Jamal, 2006). In Brazil, certain 
infectious diseases must be reported to the government, 
which is responsible for the diagnosis and treatment of 
these conditions. The high rates of morbidity and mortality 
associated with hepatitis B and C create the need for large 
investments by the government (Rantala, Laar, 2008).
According to the World Health Organization, 
approximately 3% of the world’s population (ranging 
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from 2.5 to 4.99% in the surveyed countries) is infected 
with HCV (Hepatitis C) (WHO, 2003). In Brazil, 
according to a 2010 study conducted in Brazilian state 
capitals by the Ministry of Health, the average prevalence 
of HCV is 1.6% in patients between 20 and 69 years of 
age (Brazil, 2011).
Most estimates of the prevalence of hepatitis C in 
Brazil are drawn from studies of specific populations, such 
as blood donors.
Prison populations are disproportionately affected 
by HCV, with higher incidence and prevalence observed 
in certain risk groups (Rantala, Laar, 2008; Cornberg 
et al., 2011). However, differences between the prison 
surveillance systems of different countries makes the 
comparison of epidemiological characteristics and trends 
difficult, which delays the collection of information 
useful for establishing hepatitis C prevention and control 
strategies.
In Brazil, despite the uniformity of the surveillance 
system, data collection is hampered by the large cultural 
and social differences in different regions, the difficulty 
of accessing health services (Ferreira, Silveira, 2004), and 
the frequent absence of symptoms in the early phase of the 
disease (WHO, 2003).
It is possible to detect the virus by ELISA at 49 
to 70 days following infection (Brazil, 2008). There are 
11 known genotypes in the world, of which I and III are 
the most common, and there are several subtypes. The 
existence of various genotypes and subtypes has little 
impact on the virulence and pathogenicity of the virus, 
but it does affect how the virus responds to treatment with 
interferon and ribavirin (WHO, 2003).
A major barrier to the primary prevention of hepatitis 
C is the absence of an effective vaccine or post-exposure 
prophylaxis, which limits basic preventive care to avoiding 
contact with the virus (Brazil, 2001).
The constant mutation of the viral genome sequence 
may be the reason for the existence of numerous 
quasispecies. Mutation enables the virus to evade the 
immune system and the innate immunity of the host, 
leading to the development of chronic hepatitis C in most 
patients, as well as cirrhosis (20%) and hepatocellular 
carcinoma (1-4%) (Chen, Morgan, 2006). Worldwide, 27% 
of cases of cirrhosis and 25% of cases of hepatocellular 
carcinoma are attributable to the hepatitis C virus (Perz 
et al., 2006).
As stated in Passos et al. (2012), the epidemiologic 
profile and risk factors for HCV in the population are 
of substantial importance for the establishment and 
evaluation of health policy programs. This work has the 
merit of being the first study to simultaneously establish 
the prevalence of hepatitis C in a high risk population 
(inmates) and in the non-prisoner population in the city 
of Colatina, ES, Brazil.
MATERIAL AND METHODS
This is a cross-sectional, descriptive, comparative, 
and population-based study involving 1,600 city residents 
of both sexes chosen from the general population and 730 
prisoners of both sexes from the three prisons (which 
have a total of 896 inmates) in the city of Colatina, 
Espírito Santo. All participants were over 18 years of age. 
Resident sample size (calculated sample size = 1,101) 
was calculated based on defined and acceptable standard 
error around the estimated prevalence of HCV. The 
sample was probabilistic, through cluster sampling, with 
the 22 basic health institutions as the unit sample. The 
researchers approached patients at the 22 Health United 
centers independently of their comorbidities. All persons 
included in the present study signed an informed consent 
document.
In the two male prisons (PSMECOL – Penitenciaria 
de segurança media de Colatina and CDPCOL - Centro 
de Detenção Provisória Colatina), data collection 
occurred between January and February of 2010; in the 
female prison (PRFCOL - Presídio Regional Feminino 
de Colatina), data collection occurred between July and 
August of 2010.
Due to the greater degree of difficulty of access to 
the prison population and the desire to avoid the need 
for new collection, blood was collected by finger prick 
lancets with a disposable paper filter for the “Dry Spot” 
(dried blood) testing technique. The samples were dried at 
ambient air temperature for 30 minutes or until the blood 
was completely dry and then sealed in foil-lined envelopes 
containing silica. They were then sent to the Genome 
Center for serological and molecular tests (GENOME 
CENTER, 2005). The samples were analyzed for anti-
HCV antibodies using the enzyme immunoassay method 
(HCV Rapid Test Bioeasy ®). Indeterminate results 
were considered positive for the purposes of indicating 
molecular testing confirmation.
Blood was collected from the non-prisoner 
population from May to June of 2010 in 22 districts 
located within the municipality. It was decided that data 
collection in the non-prisoner population would follow the 
same male-female ratio as the prison population sample. 
Blood samples were collected at the municipal health 
facilities of the government of Colatina, according to a 
schedule that was proposed, accepted, and disseminated 
to the population by community health workers.
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Following the administration of the interview, the 
participants, all older than 18 years of age, signed an 
informed consent document before sample collection.
The test used was the HCV Rapid Test Bioeasy®, 
qualitative immunoassay (immunochromatography 3rd 
generation) for detection of IgG antibodies specific to 
HCV, where the recombinant HCV Core (framework region 
capsid core of the genome of HCV), NS3 (the non- structural 
- protease / helicase - HCV genome), NS4 (non-structural 
region - the membrane binding - the HCV genome) and NS5 
(non-structural region - polymerase - HCV genome) were 
used as capture agents and detectors. Blood was collected 
by fingerstick with a disposable lancet, and manufacturer 
procedures were followed, with the results evaluated after 
15 to 20 minutes. Participants who tested positive received 
post-test counseling and were invited to undergo a second 
blood test in the laboratory. A portion of blood from this 
sample was separated, mixed with the anticoagulant EDTA 
(Ethylene Diamine Tetra-acetic Acid) serum was separated 
and sent to the Genome Center for confirmatory tests.
The confirmation of positive results for both the 
prisoner and non-prisoner populations was performed 
at the Genome Center by analyzing the blood sample 
for evidence of qualitative HCV-RNA using Real Time 
Polymerase Chain Reaction (RT-PCR) and TaqMan 
(which are probes that increase the specificity of the PCR), 
assessing HCV viral load using RT-PCR and TaqMan 
(both of which have a detection limit of 50 UI/mL), and 
genotyping using RT-PCR. Biopsies, genotyping, and viral 
load counts were conducted for all participants who were 
HCV-RNA positive. The biopsy was analyzed for grade 
and stage of liver injury using the Ishak scoring system 
(Ishak et al., 1995). The extent of necroinflammatory 
activity defined the grade, while the extent of fibrosis or 
the presence of cirrhosis determined the stage.
All participants were guaranteed the confidentiality of 
information obtained through this study, as well as access to 
specialized medical care and free treatment by the Unified 
Health System, according to the “Clinical Protocol and 
Therapeutic Guidelines for Viral Hepatitis C Coinfection” 
and the Brazilian Ministry of Health (Brazil, 2011).
Epi-Info (version 3.5.1) is free software that enables 
users to generate questionnaires, manage data, and conduct 
subsequent statistical analyses. It was chosen because it 
was well-known, easy to use, reliable, free, and already 
widely used in epidemiological research, as described by 
Xia et al. (2008) and Cruz et al. (2009), among others. 
Questions that were considered important in the literature 
were entered into the program to create the questionnaire. 
The questionnaire was administered to all participants, and 
their responses were entered into an Epi-Info database. 
Responses were collected from more than 1,600 people. 
The program was used to conduct statistical analysis. The 
percent frequencies of socio-demographic variables were 
determined. To analyze the association between positive 
HCV and potential risk factors, the prevalence ratio and 
associated 95% confidence interval were calculated.
The study was approved by the Ethics Committee 
(CEP) (CEP Hospital South, No. 04-30-2009) and 
authorized by the State Department of Justice (Official 
Letter 03/2010).
RESULTS
Colatina is a county in the state of Espírito Santo, 
Brazil. It has a population of 111,788 residents and is 
located between coordinates -40.63o and -19.53o, with a 
total land area of 1.417 km2 (IBGE, 2013).
Among all study participants, the prevalence of 
anti-HCV positivity was 0.4% (09/2,330), and that of 
HCV-RNA positivity was 0.3% (08/2,330), with the 
highest frequencies observed for genotypes 1 (87.5%) and 
3 (12.5%). No other genotype was found.
Five patients (three females and two males) had 
indeterminate results, and all were HCV-RNA negative.
In the prison population, the prevalence of HCV 
RNA-positivity was 0.8% (6/730), and for anti-HCV 
positivity, it was 1.0% (7/730). In the non-prisoner 
population, the prevalence of HCV-RNA and anti-HCV 
positivity was 0.1% (2/1,600).
The six biopsies revealed different degrees of fibrosis: 
one had grade 3 fibrosis (16.7%), three had grade 2 fibrosis 
(50%), and two had grade 1 fibrosis (33.3%). Two additional 
biopsies were not performed due to the transfer of prisoners 
to semi-open prisons located in other municipalities.
Of the four cases in which biopsy indicated grade 
2 or 3 fibrosis (66.7%), two came from participants 
incarcerated in PSMECOL, and two came from the non-
prisoner population. Immediate treatment was indicated by 
the results, and they were referred to specialized medical 
support (SAE-Hepatitis).
Hepatitis diagnosis was strongly associated with 
male sex (77.7%), monthly income of less than three 
minimum wages (100.0%), and low educational attainment 
(77.8% with four years of school or less). The combination 
of the three features together was 35.1%. The mean age of 
hepatitis diagnosis was 40.6 + 6.4 years. Associations were 
also present between hepatitis C infection and injected 
drug use (p = 0.00), alcohol use (p = 0.01), migraine (p = 
0.01), pain in the liver (p = 0.02), and institutionalization 
(p = 0.00), although it is not possible to generalize these 
results to the broader population (Table I).
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Injected drug use and institutionalization were the 
factors most strongly associated with hepatitis C. 
DISCUSSION
In Brazil, information about hepatitis C has become 
more accessible following the publication of several studies 
(Paltanim, Reiche, 2002; Zarife et al., 2006; Strazza et al., 
2007; Fagundes et al., 2008; Gabe, Lara, 2008; Coelho et 
al., 2009; Ferrao et al., 2009; Mousquer, Castro, 2009; Silva 
et al., 2010; Oliveira-Filho et al., 2010; Santos et al., 2011). 
Fagundes et al. (2008) found that 2.2% (10/457) of adults 
in Criciúma (Santa Catarina) were anti-HCV positive and 
that 1.53% (7/457) were HCV RNA-positive, but the study 
did not identify the HCV genotype (16). Zarife et al. (2006) 
found a prevalence of 1.5% (20/1,308) in Salvador, with 
genotype 3 (53.3%) predominating, followed by genotype 
1 (40%). Ferrao et al. (2009) studied the population of the 
district of Bebedouro, SP, and found a HCV RNA-positive 
prevalence of 8.8% (31/353). The results of this study differ 
from those studies, which may be explained by the location 
and associated risk factors.
Studies of specific populations also differ from 
the results of this study. In a study by Silva et al. (2010), 
seroprevalence for injected drug users (IDUs) was 35.6%; 
for ex-IDUs, 29.8%; and for non-IDUs, 5.3%, with 
predominance of genotype 1 (76.5%). A study conducted 
by Strazza et al. (2007) of inmates in São Paulo found a 
prevalence of 16.2%, with injectable drug use and a larger 
number of sexual partners as prevalent risk factors. A study 
conducted by Lopes et al. (2009) with 691 drug users in 
Goiania and Campo Grande revealed a prevalence of 
6.9%, with the greatest frequency of genotypes 1 (80.5%) 
and 3 (19.5%). Oliveira-Filho et al. (2010) studied 256 
blood donors in Pará, finding a prevalence of 45.3%, with 
unsafe injections, dental treatment, and sharing of razors 
as risk factors.
Paltanim and Reiche (2002) found a seroprevalence 
of 0.9% (88/10,990) anti-HCV positive in blood donors 
from Paraná, but only 0.1% (11/10,990) were HCV-RNA 
positive, 0.13% (14/10,990) exhibited indeterminate 
results, and 0.003% (38/10,990) exhibited negative results. 
In 0.28% (25/88) of participants, confirmatory testing was 
not performed.
In the prison population of Campo Grande (MS), 
Mousquer and Castro (2009) evaluated 409 inmates of 
both sexes and found a prevalence of 4.9% (20/409) of 
confirmed cases of hepatitis C, much higher than the 0.8% 
prevalence found in this study (6/730). In Aracaju, Santos 
et al. (2011) found that 3.1% (13/422) of participants 
TABLE I - Correlation of risk factors and factors associated with hepatitis C
Variable
Anti-HCV positive Anti-HCV negative
pprisoners non-prisoners
Total
prisoners non-prisoners
Total
n % n % n % n %
anti-HBc 6 0.8 2 0.2 8 722 99.2 1598 99.8 2320
injected drugs 3 0.4 1 0.1 4 40 5.8 2 0.2 42 0.00
inhaled drugs 3 0.4 1 0.1 4 403 58.5 49 4.1 452 0.09
tattoo 4 0.6 0 0.0 4 395 57.3 107 9.0 502 0.14
blood transfusion 2 0.3 0 0.0 2 70 10.2 145 12.2 215 0.23
piercing 5 0.7 0 0.0 5 470 68.2 518 43.5 988 0.48
homosexual 1 0.1 0 0.0 1 89 12.9 30 2.5 119 0.53
alcohol 6 0.9 2 0.2 8 492 71.4 379 31.8 871 0.01
previous hepatitis 3 0.4 1 0.1 4 41 6.0 111 9.3 152 0.01
migraine 5 0.7 1 0.1 6 266 38.6 311 26.1 577 0.01
hepatic pain 3 0.4 0 0.0 3 75 10.9 148 12.4 223 0.02
mental confusion 3 0.4 0 0.0 3 137 19.9 153 12.9 290 0.07
flu 2 0.3 1 0.1 3 108 15.7 176 14.8 284 0.08
depression 3 0.4 1 0.1 4 256 37.2 354 29.7 610 0.28
lack of appetite 3 0.4 0 0.0 3 219 31.8 203 17.1 422 0.28
diabetes 0 0.0 0 0.0 0 10 1.5 108 9.1 118 0.46
muscular pain 3 0.4 1 0.1 4 253 36.7 613 51.5 422 0.89
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were Ac-HCV positive (11/422), with confirmed viremia 
by PCR and a predominance of genotype 1 (90.9%). In 
another study involving prison populations, Coelho et al. 
(2009) found a prevalence of 8.7% of anti-HCV positive 
in a prison in Ribeirão Preto. In a female prison in Rio 
Grande do Sul, Gabe and Lara (2008) found 9.21% (7/76) 
anti-HCV positive. These studies revealed higher rates of 
anti-HCV positive in prison populations than in the non-
prison population, which was confirmed in this study. The 
present study, showed that the prevalence in the prison 
population was eight times higher than in the non-prison 
population, although this value (0.8%) is also well below 
those found in other prisons. It is important to mention that 
the prevalence rates in the present study are much lower 
than those cited in the literature review. This fact may 
be explained by the municipality’s size and its location 
within the state, or perhaps its distance from the main drug 
trafficking routes, but the difference in prevalence between 
the prisoner and non-prisoner groups remained very high, 
indicating that institutionalization is a substantial factor in 
the concentration of the virus.
Data published by the Ministry of Health show 
a detection rate of anti-HCV from 1999 to 2010 of 
5.3:100,000 in Brazil, and in the state of Espírito Santo, 
2.2:100,000, which is the lowest detection rate in the 
Southeast Region (Brazil, 2011). In Brazil, the reporting 
of chronic diseases such as hepatitis C are mandatory 
through the SINAM (Information System for Notifiable 
Diseases - Chronic Diseases) of the Ministry of Health, 
which reported 57 cases in Espírito Santo in 2010: 11 
cases in the capital, Vitória, and 46 within the other 71 
municipalities in the state. From 1999 to 2010, there 
were 561 total cases in Espírito Santo (Brazil, 2011). In 
2010, eight cases of HCV-RNA positive were reported 
to SINAM. Although this seems to represent a higher 
prevalence of cases in Colatina than in the state, it only 
demonstrates the importance of disclosure and availability 
of tests by the government.
In Zambia, a study by Kapembwa et al. (2011) 
showed a HCV prevalence of 1.2% among 323 HIV-
positive individuals studied. In Mexico, Burquete et al. 
(2011) reported a 1.5% prevalence, with 60.9% associated 
with blood transfusions and 25.2% associated with tattoos 
or piercings. The present study confirms tattooing as 
a risk factor as well (p = 0.049). In a study conducted 
with immigrants in Sicily, Tramuto et al. (2011) found a 
4.0% positivity rate for anti-HCV (22/393). Thornton et 
al. (2011) found an average prevalence of 0.5 to 1.2% in 
Ireland, with a strong association (80%) with drug use, and 
Flisiak et al. (2011) also showed strong association with 
drug use and male gender in Poland.
Mohtasham et al. (2007) found a 45.4% prevalence 
in injected drug user inmates in Iran, and Mahfoud et 
al. (2010) found a prevalence of 3.4% in prisoners in 
Lebanon, with strong associations with injected drug use 
and tattoos. Adjei et al. (2007) found associations with 
injected drug use and unprotected sex as the risk factors 
most strongly associated with prisoners in Ghana, Africa. 
Pellegrini, Barbanera and Gonçalves (2007) found a 
64.8% prevalence of HCV in patients with infectious 
diseases in São Bernardo do Campo.
Descriptive epidemiological observations have 
provided important clues for understanding the relationship 
between HCV and previously unknown risk factors. 
However, those studies are not representative of the entire 
population but instead are meant as indicators for potential 
risk factors that may contribute to improve the public 
health service.
Of the HCV risk factors that were evaluated in this 
study, a correlation between hepatitis C and injected drug 
use (p = 0.00) was observed. A Polish study found a higher 
prevalence in the non-prison population (1.92%) than 
among health professionals (1.42%). In Nigeria, Obienu 
et al. (2011) observed a prevalence of 4.7%, without any 
associated risk factors, which differs from the findings of 
the present work, in which risk factors such as injected 
drug use, alcohol consumption, and tattoos were strongly 
associated with hepatitis C in the prison population. 
Although the use of alcoholic beverages is not a risk 
factor for hepatitis C, alcohol use by patients with liver 
disease may facilitate the progression of hepatitis C. This 
characteristic was found in 88.8% (p=0.01) of anti HCV-
positive participants.
The identification of symptoms associated with 
hepatitis C is also quite controversial. Research by 
Leyendecker et al. (1989) showed that fatigue and 
gastrointestinal symptoms have some correlation with 
the degree of liver damage in acute forms of the disease. 
MacDonald et al. (2002) studied patients with chronic 
hepatitis C and found a correlation between hepatitis C 
infection and fatigue, depression, anxiety, and hostility, 
while Iwasaki et al. (2002) noted the absence of specific 
symptoms. In 2007, Kallman et al. demonstrated that 
fatigue is an important factor impacting the quality of 
life in those with chronic liver disease, and Henderson 
(2009) confirmed fatigue and abdominal pain as symptoms 
associated with hepatitis C in children. Kershenobich et 
al. (2011) defined genotype 1 as predominant in Latin 
America, with a prevalence of 1% to 2.3%. This study 
also involved a comparatively large number of diagnosed 
and treated patients. It is noteworthy that in Brazil, there 
is no discrimination between free persons and detainees in 
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relation to the availability of treatment. Treatment criteria 
are defined in the Ministry of Health’s “Clinical Protocol 
and Therapeutic Guidelines for Viral Hepatitis C and 
Coinfection.” The prison health care system provides the 
diagnosis and treatment of inmates. However, treatment 
requires the availability of diagnostic and screening tests. 
Regular screening, regardless of whether requested by 
medical professionals, could be a strategy to reduce the 
prevalence rate of hepatitis C.
CONCLUSION
It was possible to establish the prevalence of 
hepatitis C in the population at risk (prison inmates, 
0.8%) and in the non-prison population in the town of 
Colatina (0.1%), revealing that the prison population has 
higher rates of positivity for anti-HCV than the non-prison 
population. The data from the present study may not be 
representative for the entire population of Espírito Santo, 
but the present study includes data from more participants 
than comparable studies.
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